EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors

Daiki Murata iD, Koichi Azuma iD, Norikazu Matsuo, Kenta Murotani, Goushi Matama, Akihiko Kawahara iD, Tetsuro Sasada, Takaaki Tokito, Tomoaki Hoshino

Cancer Medicine · 2023

DOI: 10.1002/cam4.6549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Daiki Murata und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background The presence of cachexia negatively impacts the prognosis of patients with cancer. However, the mechanisms behind the development of cachexia and its prognostic impact on immunotherapy efficacy are not fully understood. Materials and Methods We retrospectively screened patients with advanced or recurrent non‐small cell lung cancer (NSCLC) who received PD‐1/PD‐L1 inhibitor monotherapy. Among 183 patients, pre‐treatment plasma samples were available from 100 patients. We defined cancer cachexia as weight loss of at least 5% during the past 6 months or weight loss of at least 2% and BMI

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmune Checkpoint InhibitorsGhrelinCachexiaProgrammed Cell Death 1 ReceptorRetrospective StudiesBiomarkers, TumorNeoplasm Recurrence, LocalPrognosisB7-H1 Antigen

Stichwörter der Autor:innen

CRPNSCLCPD-1 inhibitorcachexiachemokinecytokine

Substanzen

Immune Checkpoint InhibitorsGhrelinProgrammed Cell Death 1 ReceptorBiomarkers, TumorB7-H1 Antigen

Autor:innen und Institutionen

  • Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
  • Biostatistics Center, Kurume University School of Medicine, Fukuoka, Japan.
  • Department of Diagnostic Pathology, Kurume University Hospital, Fukuoka, Japan.
  • Cancer Vaccine and Immunotherapy Center and Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Kanagawa, Japan.

ORCID-Profile: Daiki Murata, Koichi Azuma, Akihiko Kawahara

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Murata, D., Azuma, K., Matsuo, N., Murotani, K., Matama, G., Kawahara, A., Sasada, T., Tokito, T., & Hoshino, T. (2023). Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors. Cancer Medicine. https://doi.org/10.1002/cam4.6549

Vancouver

Murata D, Azuma K, Matsuo N, Murotani K, Matama G, Kawahara A, et al. Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors. Cancer Medicine. 2023. doi:10.1002/cam4.6549

BibTeX
@article{Murata2023,
  author = {Murata, Daiki and Azuma, Koichi and Matsuo, Norikazu and Murotani, Kenta and Matama, Goushi and Kawahara, Akihiko and Sasada, Tetsuro and Tokito, Takaaki and Hoshino, Tomoaki},
  title = {Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6549}
}
Kostenlos starten →